| Biomarker ID | 1300 |
| PMID | 24394557 |
| Year | 2014 |
| Biomarker | IGFBP3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.10 (95% CI: 1.02–1.18) |
| Effect on Pathways | Pathways include: Hypoxia and p53 in the cardiovascular system, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs), TAp63 pathway, Delta Np63 pathway, Ghrelin-mediated regulation of food intake and energy homeostasis |
| Experiment | PCa Specific Survival Vs No PCa Specific Survival |
| Type of Biomarker | Prognostic |
| Cohort | 189 patients from Swedish Cohort were selected for analysis. Survival information was available for 185 patients. 22 are alive, 98 died due to prostate cancer and 65 died due to other causes. 169 samples were available for the analysis of this gene |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.013 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | IGFBP3 |